Search Results - "Flaishon, Liat"

Human placenta-derived stromal cells decrease inflammation, placental injury and blood pressure in hypertensive pregnant mice by Chatterjee, Piyali, Chiasson, Valorie L, Pinzur, Lena, Raveh, Shani, Abraham, Eytan, Jones, Kathleen A, Bounds, Kelsey R, Ofir, Racheli, Flaishon, Liat, Chajut, Ayelet, Mitchell, Brett M

“…Pre-eclampsia, the development of hypertension and proteinuria or end-organ damage during pregnancy, is a leading cause of both maternal and fetal morbidity…”
Get more information

CD74 induces TAp63 expression leading to B-cell survival by Lantner, Frida, Starlets, Diana, Gore, Yael, Flaishon, Liat, Yamit-Hezi, Ayala, Dikstein, Rivka, Leng, Lin, Bucala, Richard, Machluf, Yossy, Oren, Moshe, Shachar, Idit

“…Most mature follicular B cells circulate within the periphery in a quiescent state, without actively contributing to an acute immune response. Lasting B-cell…”
Get full text

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study by Zuckerman, Tsila, Ram, Ron, Akria, Luiza, Koren-Michowitz, Maya, Hoffman, Ron, Henig, Israel, Lavi, Noa, Ofran, Yishai, Horowitz, Netanel A., Nudelman, Olga, Tavor, Sigal, Yeganeh, Shay, Gengrinovitch, Stela, Flaishon, Liat, Tessler, Shoshi, Ben Yakar, Ruth, Rowe, Jacob M.

“…High-dose cytarabine is the backbone of acute myeloid leukemia (AML) treatment. Nevertheless, its use in older patients is considerably limited due to…”
Get full text

Anti-inflammatory effects of an inflammatory chemokine: CCL2 inhibits lymphocyte homing by modulation of CCL21-triggered integrin-mediated adhesions by Flaishon, Liat, Hart, Gili, Zelman, Einat, Moussion, Christine, Grabovsky, Valentin, Lapidot Tal, Guy, Feigelson, Sara, Margalit, Raanan, Harmelin, Alon, Avin-Wittenberg, Tamar, Shoseyov, David, Alon, Ronen, Girard, Jean-Philippe, Shachar, Idit

“…Our studies focus on the pathways that restrict homing of specific subsets of immune cells, and thereby fine-tune the immune response at specific lymphoid and…”
Get full text

IL-12 and IL-18 down-regulate B cell migration in an Ly49D-dependent manner by Hart, Gili, Flaishon, Liat, Shachar, Idit

“…In order to complete their maturation and participate in the humoral immune response, immature B cells that leave the bone marrow are targeted to specific…”
Get full text

Invariant Chain Induces B Cell Maturation in a Process That is Independent of Its Chaperonic Activity by Matza, Didi, Lantner, Frida, Bogoch, Yoel, Flaishon, Liat, Hershkoviz, Rami, Shachar, Idit

“…Early stages of B cell development take place in the bone marrow, resulting in formation of immature B cells, which migrate to the spleen for their final…”
Get full text

Frontline Aspacytarabine with Venetoclax for Older/Unfit Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase 1 Study by Altman, Jessica K., Abaza, Yasmin, Keng, Michael, Maiti, Abhishek, Koprivnikar, Jamie, Tessler, Shoshi, Blumberg, Chen, Flaishon, Liat, Ben Yakar, Ruth

“…Introduction: Venetoclax (VEN), a selective BCL2 inhibitor, in combination with hypomethylating agents (HMA) or low-dose cytarabine is currently the standard…”
Get full text

Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis by Stone, A., Zukerman, Tsila, Flaishon, Liat, Yakar, Ruth Ben, Rowe, Jacob M.

“…•Meta-analysis performed of 1822 patients from 13 studies.•For elderly/medically unfit AML patients treated with LDAC/hypomethylating agents.•15% CR (95% CI:…”
Get full text

BST-236, a Novel Cytarabine Prodrug, Is Safer and As Effective As Cytarabine in In Vivo Leukemia Models by Tessler, Shoshi, Mishalian, Inbal, Peri-Naor, Ronny, Gengrinovitch, Stela, Mayer, Raphael, Ben Yakar, Ruth, Peled, Amnon, Flaishon, Liat

“…Introduction: Acute myeloid leukemia (AML) is associated with poor outcomes in older and medically unfit patients, largely due to the severe toxicity…”
Get full text

BST-236 by Zuckerman, Tsila, Ram, Ron, Ben Yakar, Ruth, Gengrinovitch, Stela, Flaishon, Liat, Rowe, Jacob

“…Abstract only e18520 Background: Cytarabine, the first-line treatment for acute myeloid leukemia (AML), is associated with severe toxicity and high…”
Get full text

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study by Altman, Jessica K., Koprivnikar, Jamie, McCloskey, James K, Kota, Vamsi, Keng, Michael, Bixby, Dale L., Frankfurt, Olga, Emadi, Ashkan, Zuckerman, Tsila, Burch, Micah M., Levy, Moshe Y., Luger, Selina M., Bhatnagar, Bhavana, Wolach, Ofir, Ganzel, Chezi, Percival, Mary-Beth M., Roboz, Gail J., Craig, Michael, Levi, Itai, Gourevitch, Anna, Flaishon, Liat, Cohen, Darrel P., Tessler, Shoshi, Blumberg, Chen, Gengrinovitch, Stela, Ben Yakar, Ruth, Rowe, Jacob M.

“…Introduction: Cytarabine is a backbone of intensive acute myeloid leukemia (AML) chemotherapy; yet it is associated with toxicity which precludes its use in…”
Get full text

Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy by Altman, Jessica K., Koprivnikar, Jamie, McCloskey, James K., Kota, Vamsi, Frankfurt, Olga, Emadi, Ashkan, Bixby, Dale, Burch, Micah, Levy, Moshe Yair, Luger, Selina, Zuckerman, Tsila, Bhatnagar, Bhavana, Wolach, Ofir, Ganzel, Chezi, Levi, Itai, Gourevitch, Anna, Ben Yakar, Ruth, Tessler, Shoshi, Flaishon, Liat, Rowe, Jacob

“…Abstract only 7007 Background: Aspacytarabine (BST-236) is a prodrug of cytarabine, the backbone of acute myeloid leukemia (AML) standard of care chemotherapy,…”
Get full text

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b by Altman, Jessica K., Zuckerman, Tsila, Frankfurt, Olga, Luger, Selina M., Bixby, Dale L., Kota, Vamsi, Burch, Micah M., Wolach, Ofir, Levi, Itai, Gourevitch, Anna, Ram, Ron, Flaishon, Liat, Tessler, Shoshi, Gengrinovitch, Stela, Ben Yakar, Ruth, Rowe, Jacob M.

“…▪ Introduction: Aspacytarabine (BST-236) is a prodrug of cytarabine, a backbone of acute myeloid leukemia (AML) therapy. Due to its unique pharmacokinetics and…”
Get full text

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation by Altman, Jessica K., Luger, Selina M., Frankfurt, Olga, Zuckerman, Tsila, Koprivnikar, Jamie L., Kota, Vamsi, Emadi, Ashkan, Bhatnagar, Bhavana, Bixby, Dale L., Burch, Micah M., Wolach, Ofir, Levi, Itai, Gourevitch, Anna, Ram, Ron, Flaishon, Liat, Tessler, Shoshi, Gengrinovitch, Stela, Ben Yakar, Ruth, Rowe, Jacob M.

“…Introduction: BST-236 (aspacytarabine), a novel pyrimidine antagonist, is a cytarabine prodrug designed to deliver high cytarabine doses with reduced systemic…”
Get full text

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study by Zuckerman, Tsila, Ram, Ron, Koren-Michowitz, Maya, Akria, Luiza, Hoffman, Ron, Henig, Israel, Ofran, Yishai, Lavi, Noa, Horowitz, Netanel A, Nudelman, Olga, Yeganeh, Shay, Gengrinovitch, Stela, Flaishon, Liat, Ben Yakar, Ruth, Rowe, Jacob M.

“…Introduction: First line therapy of AML has not changed significantly since the 1970s and still relies on cytarabine as its backbone. Older patients or…”
Get full text

The anti‐inflammatory effects of 1,25‐dihydroxyvitamin D3 on Th2 cells in vivo are due in part to the control of integrin‐mediated T lymphocyte homing by Topilski, Ian, Flaishon, Liat, Naveh, Yaron, Harmelin, Alon, Levo, Yoram, Shachar, Idit

“…The fat soluble vitamin D3 metabolite 1,25‐dihydroxyvitamin D3 [1,25(OH)2D3], and its nuclear receptor play an important role in regulating immune responses…”
Get full text

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study by Altman, Jessica K, Zuckerman, Tsila, Koprivnikar, Jamie, McCloskey, James, Kota, Vamsi, Keng, Michael, Frankfurt, Olga, Abaza, Yasmin, Bixby, Dale L, Emadi, Ashkan, Burch, Micah, Bhatnagar, Bhavana, Luger, Selina M, Percival, Mary-Elizabeth, Wolach, Ofir, Craig, Michael, Ganzel, Chezi, Roboz, Gail, Levi, Itai, Gourevitch, Anna, Flaishon, Liat, Tessler, Shoshi, Blumberg, Chen, Gengrinovitch, Stela, Ben Yakar, Ruth, Rowe, Jacob M

“…High-dose cytarabine is associated with gastrointestinal and cerebellar toxicity, precluding its use for older or unfit patients with acute myeloid leukemia…”
Get full text

Abstract 545: PLacental eXpanded (PLX) Cell Treatment Ameliorates Preeclampsia Induced by TLR3 or TLR7 Activation in Mice by Chiasson, Valorie L, Chatterjee, Piyali, Hatahet, Mohamad, Pinzur, Lena, Abraham, Eytan, Flaishon, Liat, Chajut, Ayelet, Mitchell, Brett M

“…Abstract only PLacental eXpanded (PLX) cells (Pluristem Therapeutics Inc.) are human placenta-derived, mesenchymal-like adherent stromal cells that release…”
Get full text

IFN-gamma acts on T cells to induce NK cell mobilization and accumulation in target organs by Wald, Ori, Weiss, Ido D, Wald, Hanna, Shoham, Hadas, Bar-Shavit, Yochay, Beider, Katia, Galun, Eithan, Weiss, Lola, Flaishon, Liat, Shachar, Idit, Nagler, Arnon, Lu, Bao, Gerard, Craig, Gao, Ji-Liang, Mishani, Eyal, Farber, Joshua, Peled, Amnon

“…The mechanism(s) that regulates NK cell mobilization and the significance of this process to NK cell activity are unknown. After Con A-induced hepatitis, NK…”
Get full text

Cutting edge: anti-inflammatory properties of low levels of IFN-gamma by Flaishon, Liat, Topilski, Ian, Shoseyov, David, Hershkoviz, Rami, Fireman, Elizabeth, Levo, Yoram, Marmor, Sylvia, Shachar, Idit

“…Activation of naive T and B cells occurs only within the context of organized lymphoid tissue. Thus, the continuous recirculation of mature lymphocytes is…”
Get full text